论文部分内容阅读
近年来对免疫应答机制和同种异体移植物排斥方面的认识不断深入,使得肾移植免疫抑制有了创新和发展。单克隆抗体作为一种新型免疫抑制剂,在治疗和预防肾移植急性排斥方面取得了较好疗效。Ⅲ期临床试验中已经证实了一些单克隆抗体在预防急性排斥方面的效果,而且已成为免疫抑制治疗方案的一部分;另外一些现在正在试验,而且已经显示在免疫抑制方面的潜能,这些单克隆抗体有望成为促进器官移植特异性抗原耐受的有效制品。
In recent years, the immune response mechanisms and allograft rejection deepening awareness, making immunosuppression renal transplantation has been innovation and development. As a novel immunosuppressive agent, monoclonal antibody has achieved good results in the treatment and prevention of acute rejection of renal allografts. Phase III clinical trials have demonstrated the efficacy of some monoclonal antibodies in the prevention of acute rejection and have become part of immunosuppressive treatment regimens; others are now under test and have shown potential for immunosuppression, and these monoclonal antibodies It is expected to become an effective product for promoting the specific antigen tolerance of organ transplantation.